OBJECTIVES: This study was conducted to compare cost-related medication nonadherence among elderly Medicare enrollees with and without cancer and to describe the strategies cancer survivors used to offset the costs of medications. METHODS: Using the 2005 Medicare Current Beneficiary Survey and Medicare claims, we compared self-reported cost-related medication nonadherence (CRN), spending less on basic needs to afford medicines, and cost reduction strategies among elderly beneficiaries with and without cancer. Descriptive statistics and logistic regression models were used to characterize and compare these populations. RESULTS: In a nationally representative sample of 9,818 non-institutionalized elderly Medicare enrollees, 1,392 (14%) were classified as cancer survivors based on Medicare claims. Cancer survivors were older, more highly educated, more likely to be male and non-Hispanic, and more likely to have multiple comorbidities, poorer health status, and employer-paid medication coverage. While 10% of cancer survivors and 11% without cancer reported CRN, about 6% and 9% (p = 0.004) of those with and without cancer, respectively, reported spending less on basic needs to offset the costs of medications. Cancer survivors who reported CRN (n = 143) had lower income (62.2% versus 48.6%, p = 0.11) and were more likely to be African-American (13.0% versus 6.4%, p = 0.033) and have non-employer-based medication insurance (p = 0.002) compared to those who did not report CRN. In adjusted analyses, CRN among the two groups was similar, but with some subgroup differences noted by gender and cancer type. Use of cost reduction strategies was mostly similar among cancer survivors and those without cancer. CONCLUSION: Cost-related medication nonadherence medication is common among elderly Medicare beneficiaries, but appears to be similar among those with and without cancer.
OBJECTIVES: This study was conducted to compare cost-related medication nonadherence among elderly Medicare enrollees with and without cancer and to describe the strategies cancer survivors used to offset the costs of medications. METHODS: Using the 2005 Medicare Current Beneficiary Survey and Medicare claims, we compared self-reported cost-related medication nonadherence (CRN), spending less on basic needs to afford medicines, and cost reduction strategies among elderly beneficiaries with and without cancer. Descriptive statistics and logistic regression models were used to characterize and compare these populations. RESULTS: In a nationally representative sample of 9,818 non-institutionalized elderly Medicare enrollees, 1,392 (14%) were classified as cancer survivors based on Medicare claims. Cancer survivors were older, more highly educated, more likely to be male and non-Hispanic, and more likely to have multiple comorbidities, poorer health status, and employer-paid medication coverage. While 10% of cancer survivors and 11% without cancer reported CRN, about 6% and 9% (p = 0.004) of those with and without cancer, respectively, reported spending less on basic needs to offset the costs of medications. Cancer survivors who reported CRN (n = 143) had lower income (62.2% versus 48.6%, p = 0.11) and were more likely to be African-American (13.0% versus 6.4%, p = 0.033) and have non-employer-based medication insurance (p = 0.002) compared to those who did not report CRN. In adjusted analyses, CRN among the two groups was similar, but with some subgroup differences noted by gender and cancer type. Use of cost reduction strategies was mostly similar among cancer survivors and those without cancer. CONCLUSION:Cost-related medication nonadherence medication is common among elderly Medicare beneficiaries, but appears to be similar among those with and without cancer.
Authors: Kenneth M Langa; A Mark Fendrick; Michael E Chernew; Mohammed U Kabeto; Kerry L Paisley; James A Hayman Journal: Value Health Date: 2004 Mar-Apr Impact factor: 5.725
Authors: David U Himmelstein; Elizabeth Warren; Deborah Thorne; Steffie Woolhandler Journal: Health Aff (Millwood) Date: 2005 Jan-Jun Impact factor: 6.301
Authors: Stephen B Soumerai; Marsha Pierre-Jacques; Fang Zhang; Dennis Ross-Degnan; Alyce S Adams; Jerry Gurwitz; Gerald Adler; Dana Gelb Safran Journal: Arch Intern Med Date: 2006-09-25
Authors: R Tamblyn; R Laprise; J A Hanley; M Abrahamowicz; S Scott; N Mayo; J Hurley; R Grad; E Latimer; R Perreault; P McLeod; A Huang; P Larochelle; L Mallet Journal: JAMA Date: 2001 Jan 24-31 Impact factor: 56.272
Authors: Stella Chang; Stacey R Long; Lucie Kutikova; Lee Bowman; Denise Finley; William H Crown; Charles L Bennett Journal: J Clin Oncol Date: 2004-09-01 Impact factor: 44.544
Authors: Timothy L Lash; Matthew P Fox; Jennifer L Westrup; Aliza K Fink; Rebecca A Silliman Journal: Breast Cancer Res Treat Date: 2006-03-16 Impact factor: 4.872
Authors: Huseyin Naci; Stephen B Soumerai; Dennis Ross-Degnan; Fang Zhang; Becky A Briesacher; Jerry H Gurwitz; Jeanne M Madden Journal: Med Care Date: 2014-11 Impact factor: 2.983
Authors: Jennifer C Spencer; Cleo A Samuel; Donald L Rosenstein; Katherine E Reeder-Hayes; Michelle L Manning; Jean B Sellers; Stephanie B Wheeler Journal: Support Care Cancer Date: 2017-11-09 Impact factor: 3.603
Authors: Huseyin Naci; Stephen B Soumerai; Dennis Ross-Degnan; Fang Zhang; Becky A Briesacher; Jerry H Gurwitz; Jeanne M Madden Journal: Health Aff (Millwood) Date: 2014-08 Impact factor: 6.301